2019
DOI: 10.1159/000501496
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Stem Cell Source and Dose on Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Idiopathic Aplastic Anemia: Data from the Korean Aplastic Anemia Trials

Abstract: Objective: We aimed to evaluate the effect of stem cell source and dose on the survival of various donor subgroups, such as matched sibling donor (MSDs) and alternative donors (ADs), upon bone marrow (BM) or peripheral blood stem cell (PBSC) infusion in aplastic anemia (AA). Methods: We retrospectively investigated the effects of stem cell source and dose on allogeneic hematopoietic stem cell transplantation (alloHSCT) in AA. Results: A total of 267 patients were included in this analysis. The BM-treated group… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 25 publications
0
3
0
Order By: Relevance
“…Bone marrow is the preferred stem cell source for patients undergoing MRD transplant for AA [1,89,90]. Data from EBMT and CIBMTR showed superior outcomes with BM as compared to peripheral blood stem cells (PBSC) grafts [90,91].…”
Section: Stem Cell Source and Dosementioning
confidence: 99%
“…Bone marrow is the preferred stem cell source for patients undergoing MRD transplant for AA [1,89,90]. Data from EBMT and CIBMTR showed superior outcomes with BM as compared to peripheral blood stem cells (PBSC) grafts [90,91].…”
Section: Stem Cell Source and Dosementioning
confidence: 99%
“…However, aGVHD was significantly associated with lower OS. A recent study conducted by Kim et al showed than an age more than 31 years and previous platelet transfusions (> 86 units) have a negative impact on OS (44).…”
Section: Discussionmentioning
confidence: 94%
“…With more potent T-cell depletion, the adverse effects of PBSC may be partly overcome. Considering recent improvements to the prophylactic approach to GVHD, with the use of ATG or PTCy and the beneficial effects provided by PBSC grafts, the use of this donor source can be considered to reduce time to engraftment in selected patients with SAA and active infections [32][33][34][35][36] .…”
Section: Discussionmentioning
confidence: 99%